Phase 2 Stroke Trial, Recruiting NCT04550728 Sponsor: University of Maryland, Baltimore Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT04550728
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 85 years old
  • People who are able to walk at least 10 metres on their own, with or without a walking aid such as a cane or walker
  • People who had a stroke at least 6 months ago
  • People who have a caregiver available to help with at-home training exercises

Who may not be able to join:

  • People who have difficulty both speaking and understanding language due to their stroke (a condition called aphasia)
  • People who are unable to follow instructions that involve more than one step at a time
  • People who are currently taking part in another rehabilitation program focused on their legs
  • People who have severe pain in the leg that was affected by their stroke
  • People who have significant stiffness in their ankle that limits movement beyond a certain point (confirm with trial site)
  • People who have an implanted electronic device, such as a pacemaker, spinal cord stimulator, or deep brain stimulator, because the electrical stimulation used in this trial may interfere with how those devices work

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 410 706 2145

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 August 2021
Est. completion
1 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Fugl-Meyer Lower Extremity; Fugl-Meyer Lower Extremity; Fugl-Meyer Lower Extremity; Dorsiflexion active range of motion; Dorsiflexion active range of motion; Dorsiflexion active range of motion; 6 minutes walking test; 6 minutes walking test; 6 minutes walking test; Medical thickness of medial gastrocnemius muscle and tibial anterior muscle; Medical thickness of medial gastrocnemius muscle and tibial anterior muscle; Medical thickness of medial gastrocnemius muscle and tibial anterior muscle; Muscle fiber pennation angle of medial gastrocnemius muscle and tibial anterior muscle; Muscle fiber p...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov